
Bradley G. Somer, MD, associate professor of hematology/oncology, head of strategic expansion/development, University of Tennessee West Cancer Center, discusses the potential for immunotherapy combinations in patients with Metastatic Renal Cell Carcinoma (mRCC). In the CheckMate-214 study, the combination of Nivolumab (Opdivo) and Ipilimumab (Yervoy) showed a clear survival advantage over the frontline standard-of-care Sunitinib (Sutent)… Read more »